Early Detection of Vulvovaginal Graft-Versus-Host Disease: An Integrative Review.


Journal

Journal of the advanced practitioner in oncology
ISSN: 2150-0878
Titre abrégé: J Adv Pract Oncol
Pays: United States
ID NLM: 101550346

Informations de publication

Date de publication:
Sep 2021
Historique:
entrez: 21 10 2021
pubmed: 22 10 2021
medline: 22 10 2021
Statut: ppublish

Résumé

Vulvovaginal graft-vs.-host disease (VVGvHD) is a condition caused by a T-cell mounted immune response after allogeneic hematopoietic stem cell transplant (alloHSCT), which can lead to sclerotic changes of the external genital organs. A common complication of alloHSCT, VVGvHD is underreported and underdiagnosed in female patients. Without detection and treatment, VVGvHD can progress to complete obliteration of the vaginal canal requiring surgical intervention in severe cases. This review summarizes findings to assist providers in detecting and treating VVGvHD. It utilized PubMed, Scopus, and CINAHL databases. Inclusion criteria consisted of female patients, a history of stem cell transplantation, and a history of VVGvHD. Studies not published in English and dated more than 15 years were excluded. After the evaluation of 333 articles, 10 were included based on relevance and applicability. Limitations of this review included small sample sizes, retrospective nature of articles, and lack of randomized control trials. Early identification of VVGvHD requires identifying the rate of occurrence and risk factor profile, recognizing the presenting symptoms, improving VVGvHD assessment techniques, ascertaining when to biopsy, and establishing clinically targeted surveillance programs. For female patients who have undergone alloHSCT, targeted surveillance for early identification of VVGvHD results in earlier treatment initiation. Subsequently, this can improve sexual health, partner relationships, and quality of life in patients after stem cell transplant.

Identifiants

pubmed: 34671502
doi: 10.6004/jadpro.2021.12.7.6
pii: 2021.12.7.6
pmc: PMC8504929
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

725-737

Informations de copyright

© 2021 Harborside™.

Déclaration de conflit d'intérêts

The authors have no conflicts of interest to disclose.

Références

J Low Genit Tract Dis. 2017 Apr;21(2):157-160
pubmed: 27977542
Bone Marrow Transplant. 2006 Oct;38(8):567-72
pubmed: 16953208
Haematologica. 2003 Oct;88(10):1163-8
pubmed: 14555313
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Obstet Gynecol Clin North Am. 2017 Sep;44(3):475-492
pubmed: 28778644
Blood. 2011 Sep 8;118(10):2679-87
pubmed: 21719600
Biol Blood Marrow Transplant. 2019 Nov;25(11):e331-e343
pubmed: 31394266
Asia Pac J Oncol Nurs. 2017 Apr-Jun;4(2):116-119
pubmed: 28503642
J Sex Med. 2010 Sep;7(9):3216-25
pubmed: 20626607
Biol Blood Marrow Transplant. 2019 Dec;25(12):2408-2415
pubmed: 31325588
Obstet Gynecol. 2007 Nov;110(5):1041-9
pubmed: 17978118
Biol Blood Marrow Transplant. 2016 Feb;22(2):378-379
pubmed: 26431628
Transplantation. 2012 Jun 27;93(12):1265-9
pubmed: 22466789
Acta Obstet Gynecol Scand. 2018 Sep;97(9):1122-1129
pubmed: 29752810
Climacteric. 2019 Dec;22(6):603-609
pubmed: 31315476
Hematol Transfus Cell Ther. 2019 Jan-Mar;41(1):69-75
pubmed: 30793107
Biol Blood Marrow Transplant. 2014 Jun;20(6):806-11
pubmed: 24594123
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383

Auteurs

Payton L Ten Hagen (PL)

The University of Texas MD Anderson Cancer Center, Houston, Texas.

Christi Bowe (C)

The University of Texas MD Anderson Cancer Center, Houston, Texas.

Joyce E Dains (JE)

The University of Texas MD Anderson Cancer Center, Houston, Texas.

Classifications MeSH